JANX FY2025 EPS Estimate Boosted by Cantor Fitzgerald

Janux Therapeutics, Inc. (NASDAQ:JANX) – Stock analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for Janux Therapeutics in a research note issued on Monday, May 12th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings of ($3.28) per share for the year, up from their prior estimate of ($3.32). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share.

Several other brokerages also recently issued reports on JANX. Scotiabank reduced their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Janux Therapeutics has a consensus rating of “Buy” and a consensus target price of $95.25.

Janux Therapeutics Trading Up 2.9%

JANX stock opened at $23.27 on Wednesday. The stock’s 50 day simple moving average is $28.76 and its 200 day simple moving average is $40.94. Janux Therapeutics has a 12-month low of $22.48 and a 12-month high of $71.71. The firm has a market cap of $1.38 billion, a P/E ratio of -19.89 and a beta of 3.24.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,333 shares of the company’s stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $32.03, for a total value of $106,755.99. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,630,912.17. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the purchase, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This represents a 3.67% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 10,001 shares of company stock valued at $313,964 in the last quarter. Corporate insiders own 8.10% of the company’s stock.

Institutional Trading of Janux Therapeutics

Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its position in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock worth $45,000 after purchasing an additional 1,574 shares in the last quarter. US Bancorp DE boosted its position in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after purchasing an additional 1,658 shares during the last quarter. Russell Investments Group Ltd. grew its position in shares of Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares during the period. GF Fund Management CO. LTD. acquired a new position in Janux Therapeutics during the fourth quarter valued at approximately $59,000. Finally, FNY Investment Advisers LLC grew its holdings in shares of Janux Therapeutics by 6,928.6% in the 1st quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after buying an additional 2,425 shares during the period. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.